Author Archive

Dr. Valentín Fuster awarded Doctor Honoris Causa and Presidential Honorary Award in Cyprus

On his recent visit to Cyprus, Dr. Valentín Fuster, General Director of the Spanish National Center for Cardiovascular Research (CNIC), President of the Mount Sinai Fuster Heart Hospital, and Physician-in-Chief at Mount Sinai Hospital in New York, was distinguished with three significant recognitions that underscore his global leadership in cardiovascular medicine.

During an official ceremony, the President of Cyprus, Mr. Nikos Christodoulides, presented Dr. Fuster with the Presidential Honorary Award, acknowledging his outstanding contributions to cardiovascular health and his lifelong commitment to advancing medical science. In addition, the European University of Cyprus conferred upon him the title of Doctor Honoris Causa, a distinction reserved for individuals whose scientific achievements and dedication have had a profound impact on society.

As part of the visit, Dr. Fuster delivered the Honorary Keynote Lecture at the 13th International Medical Congress organized by the European University of Cyprus, where he addressed the latest advances in cardiovascular prevention and innovation, sharing insights that will shape the future of global health.

“It is a privilege to receive these recognitions. I consider them a tribute not only to my work, but also to the collective efforts of the scientific community to improve cardiovascular health worldwide. ‘Collaboration and education remain essential to achieving lasting progress,’ said Dr. Fuster.

His research covers landmark mechanistic studies, diagnostic and treatment breakthroughs, and innovative strategies to address the global public health challenge of non-communicable diseases by promoting cost-effective prevention and treatment. These achievements have transformed clinical practice worldwide, reaffirming Dr. Fuster’s commitment to advancing cardiovascular health through research, education, and knowledge dissemination.

Go to Source

InCAEM, a New Cutting-edge Technological Infrastructure for the Study of Materials for Energy Transition

On November 24th, as part of the closing of the Advanced Materials program of Complementary Plans, this new scientific facility was inaugurated. InCAEM will be crucial to positioning Catalonia and Spain as key players in the development of materials and technologies that promote green energy and a sustainable economy.

Go to Source

Active Galactic Nuclei as Laboratories for Fundamental Physics

Image
Active Galactic Nuclei as Laboratories for Fundamental Physics
Seminar

Active Galactic Nuclei as Laboratories for Fundamental Physics

Date
Place
Albert Cornet Seminar Room, F324, 3rd Floor

Abstract: The vicinity of supermassive black holes at the center of Galaxies represents one of the most extreme environments in the Universe. In Active Galactic Nuclei (AGN), intense gravitational fields, relativistic particle acceleration, strong magnetic fields, and dense ambient gas and radiation coexist in conditions unmatched by other astrophysical sources or Earth-based laboratories. Recent high-energy neutrino observations from the IceCube collaboration and their electromagnetic counterparts from AGN have revolutionized the field of multi-messenger astronomy, providing the first direct window into the hadronic and leptonic processes operating at these cosmic accelerators, and opening new opportunities to test fundamental physics at energies and densities beyond terrestrial reach.

Here I will discuss how these environments can be exploited as laboratories for fundamental physics. I will first focus on dark matter–Standard Model interactions, showing how dark matter scattering with cosmic rays, neutrinos and gamma-rays can can lead to observable signatures on Earth. Second, I will consider other exotic phenomena that may occur independently on the dark matter background in these environments, such as photon-axion-like particle oscillations and microscopic black hole production from cosmic-ray collisions. Finally, I will conclude by showing how AGN can boost the cosmic neutrino background to higher energies via Standard Model processes, giving us a viable and promising pathway to detect the oldest particles in the Universe.

Go to Source

Relativistic Navier-Stokes for the Quark-Gluon Plasma and Neutron Star Mergers

Image
Relativistic Navier-Stokes for the Quark-Gluon Plasma and Neutron Star Mergers
Seminar

Relativistic Navier-Stokes for the Quark-Gluon Plasma and Neutron Star Mergers

Date
Place
Pere Pascual V5.07 Room

Abstract: Relativistic theories of dissipative fluids have long been known to suffer from pathologies. In recent years, a novel consistent formulation has been proposed: a well-posed and causal version of the relativistic Navier-Stokes equations. This theory provides a promising alternative to existing approaches and represents a key development in the foundations of relativistic hydrodynamics. We will introduce this emergent framework, motivate its application in addressing state-of-the-art challenges, and present progress in numerical implementations. In particular, we will report on its success in describing experimental data from heavy-ion collisions at the LHC, providing a proof of principle that it offers a viable solution to the causality issues found in current models. We will also discuss ongoing work towards the simulations of viscous neutron star mergers.

Go to Source

Un equipo de investigadores del CSIC identifica un fármaco de amplio espectro para el tratamiento de enfermedades respiratorias de origen viral

La colaboración de cuatro equipos científicos del Consejo Superior de Investigaciones Científicas (CSIC), liderados por el bioquímico Eduardo Rial, del Centro de Investigaciones Biológicas Margarita Salas, ha permitido identificar un fármaco para el tratamiento de enfermedades respiratorias de origen viral, el dicloroacetato (DCA). El proyecto de investigación se inició en 2020, en el marco de la Plataforma Temática Interdisciplinar Salud Global del CSIC, creada ese año como respuesta a la pandemia de la COVID-19.

El DCA actúa bloqueando los cambios que los virus inducen en el metabolismo de las células infectadas para que estas produzcan los componentes necesarios para generar nuevas partículas virales. El estudio ha demostrado su eficacia frente a tres virus respiratorios de gran impacto en la salud humana como son el SARS-CoV-2, el virus del resfriado común y el virus respiratorio sincitial (RSV), responsable de la mayoría de los casos de bronquiolitis.

El trabajo, publicado en la revista International Journal of Molecular Sciences, se ha centrado en la evaluación de la actividad antiviral de fármacos utilizados frente al cáncer. Según explica Eduardo Rial, “la aproximación científica del proyecto se basaba en que era conocido que esa reprogramación metabólica inducida por los virus es similar a la que ocurre en las células tumorales y que se conoce como efecto Warburg. Se buscaba, por tanto, el reposicionamiento de fármacos con actividad antitumoral y cuyas dianas estuvieran en una ruta de señalización que pudiera ser clave para el cambio metabólico”.

El reposicionamiento de fármacos es una estrategia que permite reducir significativamente el tiempo y los recursos necesarios para llevar una molécula a la clínica, ya que se dispone de información previa sobre su farmacología y posibles efectos secundarios. Consiste en utilizar un compuesto desarrollado originalmente para tratar una enfermedad con un propósito terapéutico diferente.

Bruno Hernáez, virólogo del Centro de Biología Molecular Severo Ochoa (CSIC-UAM) y miembro del equipo investigador, destaca la importancia de utilizar como diana antiviral aquellos procesos celulares necesarios para la replicación de los virus. “Cuando se ataca una diana celular, como el metabolismo, se evita que el virus desarrolle resistencia frente a los tratamientos, lo que podría hacerlos ineficaces. Además, esta estrategia podría funcionar también contra otros virus”, explica.

Los autores subrayan la importancia del modelo preclínico avanzado empleado en los ensayos con el DCA: epitelios 3D estratificados que se asemejan a la estructura de los epitelios de las vías respiratorias y que, por tanto, reproducen las condiciones en las que se produce la infección viral en los pacientes.

El dicloroacetato, un viejo conocido

La glucosa es una de las principales fuentes de energía de nuestras células. Cuando hay suficiente oxígeno, uno de los productos de su degradación, el piruvato, se oxida en la mitocondria para generar energía. En ausencia de oxígeno, el piruvato se transforma en ácido láctico, que se acumula en el exterior de las células. Esta acumulación es la responsable de las conocidas “agujetas” tras un ejercicio físico intenso.

Las células, en algunas situaciones, producen ácido láctico, aunque dispongan de oxígeno. Este cambio metabólico, conocido como efecto Warburg, fue descrito en 1927 por Otto Warburg como una característica de las células tumorales, que activan esta vía para multiplicarse rápidamente. Sin embargo, el efecto Warburg también se observa en células sanas que proliferan activamente o en procesos inflamatorios de distintos orígenes. Como se ha dicho anteriormente, los virus también inducen el efecto Warburg en las células infectadas.

El complejo piruvato deshidrogenasa (PDC) es el punto clave que determina el destino metabólico del piruvato: cuando este complejo se inactiva, el piruvato no puede oxidarse en la mitocondria y se convierte en ácido láctico. En los años 70 se descubrió que el dicloroacetato (DCA) reduce la acidosis láctica precisamente porque reactiva el PDC, restaurando así el metabolismo mitocondrial del piruvato. Desde entonces, el DCA se ha venido utilizando en el tratamiento compasivo de la acidosis láctica congénita en niños, una enfermedad rara causada generalmente por alteraciones genéticas que conllevan una baja actividad de este complejo.

Actualmente, el DCA se usa como fármaco en estudio para el tratamiento de otras patologías que reducen la actividad del PDC, como el cáncer (usado preferentemente en terapia combinada), la endometriosis o la hipertensión pulmonar. En todos estos casos hay ensayos clínicos en desarrollo, aunque el DCA aún no cuenta con la autorización de agencias reguladoras como la FDA o la EMA.

Los autores señalan que los tratamientos crónicos prolongados (semanas o meses) con DCA pueden tener como efecto secundario una neuropatía periférica leve, caracterizada por hormigueo o entumecimiento de los dedos, que desaparece al suspender la medicación. Sin embargo, como el tratamiento de una infección viral debería requerir solo unos días de administración, los efectos neurológicos serían poco probables. En cualquier caso, el siguiente paso deberá ser el desarrollo de ensayos clínicos específicos que permitan comprobar la eficacia del DCA frente a infecciones víricas del tracto respiratorio.

 

Referencia: Human Small Airway Epithelia Reveal Dichloroacetate as a Broad-Spectrum Antiviral Against Respiratory Viruses. Paula Martínez de Iturrate, Bruno Hernáez, Patricia de los Santos, Yolanda Sierra-Palomares, Alba García-Gómez, Alonso Sánchez-Cruz, Catalina Hernández-Sánchez, Luis Rivas, Margarita del Val and Eduardo Rial. Int. J. Mol. Sci. 2025, 26(20), 9853; https://doi.org/10.3390/ijms26209853

La entrada Un equipo de investigadores del CSIC identifica un fármaco de amplio espectro para el tratamiento de enfermedades respiratorias de origen viral se publicó primero en Centro de Biología Molecular Severo Ochoa.

Go to Source

Una delegación educativa de Bulgaria visita el CIMCYC para conocer el modelo de Neuromindset

Bulgaria neuromindset
Una delegación, compuesta por autoridades gubernamentales en educación, responsables de instituciones educativas y especialistas en primera infancia de Bulgaria, ha visitado el Centro de Investigación Mente, Cerebro y Comportamiento de la Universidad de Granada para conocer el modelo de Neuromindset, la spin-off universitaria que aplica los avances de la neurociencia cognitiva al ámbito educativo.
Seguir leyendo

Go to Source

Bulgarian Educational Delegation Visits the CIMCYC to Learn About the Neuromindset Model

Bulgaria neuromindset
Una delegación, compuesta por autoridades gubernamentales en educación, responsables de instituciones educativas y especialistas en primera infancia de Bulgaria, ha visitado el Centro de Investigación Mente, Cerebro y Comportamiento de la Universidad de Granada para conocer el modelo de Neuromindset, la spin-off universitaria que aplica los avances de la neurociencia cognitiva al ámbito educativo.
Seguir leyendo

Go to Source

Moltes felicitats, Dra. Sunyer!

Neus Sunyer, a PhD student who is under Prof. JR Galán-Mascaros and Prof. Katherine Villa supervision has successfully defended her PhD thesis entitled “Enantioselective Carbyne Transfer via Chiral Rh-Carbynoids” publicly on Friday, November 21.

The members of the evaluation committee were Dr. Sara Goberna Ferrón (Universitat Politècnica de València), Dr. Vanesa Lillo (ICIQ) and Dr. Jesús González Cobos (University of Lyon, France).

La entrada Moltes felicitats, Dra. Sunyer! se publicó primero en ICIQ.

Go to Source

Moltes felicitats, Dr. Esteve!

Josep Esteve, a PhD student who is under Prof. Marcos Garcia Suero supervision has successfully defended his PhD thesis entitled “Enantioselective Carbyne Transfer via Chiral Rh-Carbynoids” publicly on Friday, November 21.

The members of the evaluation committee were Prof. Miquel Costas Salgueiro (Universitat de Girona), Prof. Rubén Martín Romo (ICIQ) and Prof. Berit OIofsson (Stockholm University, Sweden)

Josep Esteve is from Parets del Vallès, near Barcelona. He studied chemistry at UAB and completed his MSc in Chemistry in Uppsala, Sweden, before joining ICIQ. In his free time, he enjoys playing the saxophone, especially ska-jazz music.

What is your thesis about?

In my thesis I describe the development of two new reactions involving Rh-carbynoids, as a part of a carbyne transfer platform methodology program. In one of them we do an enantioselective single-carbon insertion into alkenes (the first enantioselective skeletal-editing modification of this kind!), and in the other one, we generate for the first time alkyl–I(III) Rh-carbynoids and explore its reactivity. With these methodologies we seek to help medicinal chemists to tackle complex drug molecules faster, and this is why there is a complete mechanistic study in both projects.

What triggered your interest for the subject of your thesis?

I always liked reactive carbon species as intermediates in chemical reactions, and the beauty on controlling them to make precise changes in molecules. For this reason, carbynes have a great potential. I liked the fact that not a lot of research was conducted about them, and that we could change this with my thesis.

What applications can your thesis have in the future?

I hope it can be used one day in the pharmaceutical industry, to access complex biologically active molecules that hopefully can treat a disease. And who knows, maybe it will be used in a ton-scale factory one day to make a new drug!

The thing that I like most about my thesis is…. 

The mechanistic discussion of the reactions. All the experiments devoted to elucidate how the reaction is taking place, in each individual step.

From the lessons learnt (or skills developed) at ICIQ, which one do you value the most?

The value you put in your work. Here in ICIQ I realized how you need to defend your results, give them the importance they deserve, and use them to step forward your research.

What advice do you have for someone who’s starting their PhD now?

Try all the experiments you are curious about, the PhD is not just about doing the work you need to get done, but also about exploring new things and be excited about science.

Who/What has been your biggest influence/motivation?

I think my main motivation comes from the colleagues that started with me the PhD. Seeing them pushing forward their projects and getting interesting results makes you want to be at the same level.

What is your favourite molecule? 

Rh2(S-NTTL)4. Its crystal structure is a beautiful bowl shape, and it has been very useful in my projects.

If you were a piece of lab equipment, what would you be?

The SFC (supercritical fluid chromatography). It has been the instrument in the lab I spent more time with, and is extremely helpful for separating different enantiomers of a molecule.

Tell us something about you that people might not know… 

I know how to play diabolo and ride a unicycle.

La entrada Moltes felicitats, Dr. Esteve! se publicó primero en ICIQ.

Go to Source

ICCUB Colloquium by prof. Zohreh Davoudi

Image
default_iccub_colloquia
ICCUB Colloquium

ICCUB Colloquium by prof. Zohreh Davoudi

Date
Place
Aula Magna Enric Casassas and YouTube Live

Abstract: TBA

Go to Source

CSIC X+, 27 Dec 2025

CSIC and Fundación Mediterráneo share the positive energy of science in a show for the whole family

  • On 27 December at 5:30 p.m., the Foundation’s Aula de Cultura will become a large laboratory where audiences can experience science, art, and a wide range of emotions through the CSIC X+ initiative.
  • The event is free of charge, with prior registration required from 20 November at csicxmas.com
  • The website also hosts videos with experiments, tips, and games to keep scientific curiosity active throughout the year.

Dr. X+, played by CSIC astrophysicist Daniel Guirado, is one of the main characters of the fifth edition of CSIC X+. Source: CSIC

The Spanish National Research Council (CSIC) has presented this week the fifth edition of its Christmas programme CSIC X+. Under the title ‘The X+ Good Energy’, the initiative invites family audiences to enjoy a travelling show that blends science and art through emotions, and launches a new website (csicxmas.com) featuring experiments, tips, and science-based games to learn while having fun 365 days a year.

Alicante, the X+ stage

The X+ show will visit Alicante on Saturday, 27 December. At 5:30 p.m., the Fundación Mediterráneo’s Aula de Cultura will be transformed into a unique laboratory where families can experience science live.

There, a group of daring characters led by the charismatic Dr. X+, played by Daniel Guirado, musician and astrophysicist at the Institute of Astrophysics of Andalusia (IAA-CSIC), will take the audience on a thrilling journey through a wide range of phenomena studied at the CSIC, including the polar regions, the oceans, sound waves, the human brain, and eclipses.

The session will feature guest appearances by Susana Rodríguez, Director of the Institute of Biomedicine of Valencia (IBV-CSIC), and neuroscientist Juan Antonio Sánchez Alcañiz from the Institute of Neurosciences (IN), a joint center of the CSIC and the Miguel Hernández University of Elche (UMH). Admission is free, with prior registration required via the website csicxmas.com, starting on November 20.

“It is a great satisfaction for me to take part in an initiative like CSIC X+, which achieves something essential: bringing science into the realm of emotion and curiosity,” says Sánchez Alcañiz, who leads the Neurogenetic Bases of Behavior laboratory at the IN. “At our centre, we work every day to understand how the brain functions, from the most basic neuronal circuits to the processes that enable us to think, learn, and remember. Being able to share these advances with families, in such a playful and accessible setting, is an extraordinary opportunity to bring research closer to society and to inspire new scientific vocations.”

“Since its first edition, CSIC X+ has been a space where science is experienced as something shared,” explains Pura Fernández, Deputy Vice President for Scientific Culture and Citizen Science at the CSIC. “In its fifth anniversary year, the project expands its reach with a hybrid programme and a new approach: bringing this festive celebration of science to more places and more moments throughout the year,” she adds.

A whole year of X+ content

After its premiere in Mérida (December 6) and stops in Fuengirola (December 14), Madrid (December 23), and Alicante (December 27), the show will conclude its tour in Santiago de Compostela on January 2.

In addition to enjoying science beyond the classroom and the Christmas season, the project has launched a dynamic website (csicxmas.com) where families, teachers, and curious people of all ages can access videos in which Dr. X+ shares experiments and tips, as well as stories and challenges created by the X+ team. All these resources fall under the umbrella of The X+ Method, which invites audiences to observe, ask questions, experiment, and share science.

Five years of science and Christmas

The CSIC X+ initiative began in 2021 as a Christmas science and technology camp for children at the CSIC’s headquarters in Madrid. The format was repeated in 2022, incorporating a large immersive brain in which visitors could discover Santiago Ramón y Cajal’s major contributions to the development of neuroscience. In 2023, the camp was complemented by three sound-based encounters with musical artists such as Anni B Sweet, Niño de Elche, and Tulsa, commemorating the centenary of radio in Spain. A year later, the children’s activities moved to the National Museum of Natural Sciences (MNCN-CSIC), and the sound encounters travelled beyond Madrid to Gijón, Zaragoza, and Granada. The content of that edition focused on polar expeditions.

In 2025, The X+ Good Energy will revisit some of the themes explored in previous editions—both on stage and online—and will also highlight solar eclipses, an astronomical phenomenon that will be visible from Spain on three occasions between 2026 and 2028.

The purpose of this fifth edition is summed up in the following manifesto:

The X+ Good Energy
is not stored,
is not exhausted,
it is shared.
It lights up,
it spreads,
and it is celebrated.
It is the spark that brings together science and emotion,
arts and discoveries,
childhood, family, and futures.

Source: CSIC Cultura Científica

La entrada CSIC X+, 27 Dec 2025 se publicó primero en Instituto de Neurociencias de Alicante.

Go to Source

IMDEA Energía refuerza su papel como puente entre la industria y la investigación sostenible en GENERA 2025

La entrada IMDEA Energía refuerza su papel como puente entre la industria y la investigación sostenible en GENERA 2025 se publicó primero en IMDEA ENERGÍA.

Go to Source

Sidebar